Glyprolins & PGP hybridsГлипролины
A family of short peptides rich in glycine and proline, including PGP and experimental peptides built by adding PGP to another sequence.
What the studies found
Animal research · 2006
Peptidergic correction of behavior in adult progeny of albino rats exposed to acute hypoxia during early organogenesis
- Female offspring
- Authors report prevention of the measured negative behavioral consequences
- Male offspring: residual deficit
- Most measured effects improved, but delayed physical development persisted
Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.
Study notes · methods, sources and limitations
Participants or model Rat offspring exposed to hypoxia on gestation days 9–10; n unavailable in abstract
Design Intranasal Pro-Gly-Pro to pups on postnatal days 13–15, 1 mg/kg; adult physical development, spontaneous behavior and training evaluated.
Important limitations
- Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety.
- Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety. Sample sizes, numerical scores, masking and litter-level analyses unavailable in the abstract. Sex-specific qualitative results are not quantified effect estimates.
Bulletin of experimental biology and medicine. 2006;142(1):32-4. PMID 17369896 · Original journal publication
Lab research · 2017
Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells
Study of multiple preparations
- Selank neuronal differentiation
- GABA-positive neuron ratio decreased by 61%Selank 100 µM versus control; not an in-vivo malformation endpoint
- PGP proliferation
- Small but significant inhibition at 10 µMNo numerical inhibition magnitude in abstract
- Semax cell survival
- Increased survival at 10 and 0.1 µM during serum deprivationCell-stress endpoint, not reproductive toxicology
Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.
More reported outcomes
- Safety-inference limit
- The authors infer no embryonic/fetal toxicity; this culture model does not establish that claim in pregnancy
Study notes · methods, sources and limitations
Participants or model Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses
Design Cultured mouse embryonic stem cells; proliferation, survival during serum deprivation and neuronal differentiation after several peptides and growth-factor controls.
Important limitations
- Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes.
- Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes. The study also found reduced cell differentiation and proliferation. Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.
Bulletin of experimental biology and medicine. 2017;163(6):731. PMID 29063333 · Original journal publication
Animal research · 2014
[Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia].
PGP altered expression of 29 genes at three hours and 57 at 24 hours; immune-response genes were predominantly downregulated at the later time point.
Study notes · methods, sources and limitations
Participants or model Rat cortical tissue at 3 and 24 hours after permanent focal ischemia
Important limitations
- PGP was tested separately; results cannot be assigned wholesale to Semax or Selank. Gene-expression endpoints do not establish clinical stroke efficacy.
Molekuliarnaia biologiia; 2014 · Indexed abstract
About Glyprolins & PGP hybrids
Names in this research collection
PGP · Pro-Gly-Pro · PG · GP · PGPL · Gly-Hyp · Pro-Hyp-Gly · Gly-Pro-Hyp · Gly-Hyp-Pro · Hyp-Gly-Pro · GHyp · PHypG · GPHyp · GHypP · HypGP · GPE
Research background
A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.
Pregnancy and offspring research
Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.
Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety.
Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗
- Compound class
- Peptide research family
- Research collection
- Neuropeptide research · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
No human treatment trial assessed for this family
Study methods
Member-specific studies; patents and archival leads identified separately
Independent replication
Independent replication not established by the records collected here
Source access
Primary abstracts, selected full texts, patents and explicit retrieval targets
Safety evidence
Cell and animal effects do not establish human safety; analogues may differ
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Animal research · 2006
Peptidergic correction of behavior in adult progeny of albino rats exposed to acute hypoxia during early organogenesis
Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.
Study notes and original source
Peptidergic correction of behavior in adult progeny of albino rats exposed to acute hypoxia during early organogenesis
glyprolins · Original journal publication
Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered
Graf AV, Maklakova AS, Krushinskaya YV, Sokolova NA · Bulletin of experimental biology and medicine. 2006;142(1):32-4. PMID 17369896
Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.
Results and tables
Reported findings and study design
Findings described in words
Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.
Intranasal Pro-Gly-Pro to pups on postnatal days 13–15, 1 mg/kg; adult physical development, spontaneous behavior and training evaluated.
Population or model Rat offspring exposed to hypoxia on gestation days 9–10; n unavailable in abstract
Dose, route and schedule
Pro-Gly-Pro 1 mg/kg intranasally to pups on postnatal days 13–15, following maternal hypoxia on gestation days 9–10. Research description, not human-use advice.
Protocol source ↗ · Indexed original abstract; full methods and outcome tables not recovered
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Female offspring | Authors report prevention of the measured negative behavioral consequences | |
| Male offspring: residual deficit | Most measured effects improved, but delayed physical development persisted |
Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety. Sample sizes, numerical scores, masking and litter-level analyses unavailable in the abstract. Sex-specific qualitative results are not quantified effect estimates.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Rat offspring exposed to hypoxia on gestation days 9–10; n unavailable in abstract
- Source reviewed
- Indexed original abstract; full methods and outcome tables not recovered
Study limitations
- Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety.
- Sample sizes, numerical scores, masking and litter-level analyses unavailable in the abstract. Sex-specific qualitative results are not quantified effect estimates.
Reviewed 2026-11-08.
Lab research · 2017
Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells
Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.
Study notes and original source
Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells
semax, selank, glyprolins · Original journal publication
Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered
Kobylyanskii AG, Zolotarev YA, Andreeva LA, Grivennikov IA, Myasoedov NF · Bulletin of experimental biology and medicine. 2017;163(6):731. PMID 29063333
Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.
Results and tables
Reported findings and study design
Reported findings
Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.
Cultured mouse embryonic stem cells; proliferation, survival during serum deprivation and neuronal differentiation after several peptides and growth-factor controls.
Population or model Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Selank neuronal differentiation | GABA-positive neuron ratio decreased by 61% | Selank 100 µM versus control; not an in-vivo malformation endpoint |
| PGP proliferation | Small but significant inhibition at 10 µM | No numerical inhibition magnitude in abstract |
| Semax cell survival | Increased survival at 10 and 0.1 µM during serum deprivation | Cell-stress endpoint, not reproductive toxicology |
| Safety-inference limit | The authors infer no embryonic/fetal toxicity; this culture model does not establish that claim in pregnancy |
Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes. The study also found reduced cell differentiation and proliferation. Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses
- Source reviewed
- Indexed original abstract; full methods and outcome tables not recovered
Study limitations
- Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes.
- The study also found reduced cell differentiation and proliferation.
- Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.
Reviewed 2026-11-08.
Experiment described in a patent · 2018
GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
Study notes and original source
GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Сергей Борисович Середенин, Татьяна Александровна Гудашева, Ксения Николаевна Колясникова, Елена Александровна Кузнецова, Татьяна Александровна Воронина, Милада Альнордовна Яркова, Татьяна Алексеевна Антипова, Светлана Александровна Литвинова, Николай Николаевич Золотов · RU2646604C2 · patent family 59497169
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
Results and tables
Reported patent results
Findings described in words
The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.
GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
Population or model GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Metabolic identity | CPG formation observed during incubation with plasma and brain homogenate | Supports a precursor/metabolite relationship; not a human clinical exposure estimate |
| Cell-injury comparison | Concentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell model | No quantitative cell-survival percentage independently transcribed |
| Animal findings | Increased survival time under experimental hypoxia and anxiolytic-like behavioral findings reported at selected exposures | Different compounds and assays must not be pooled |
These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.
- These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Animal research · 2014
[Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia].
PGP altered expression of 29 genes at three hours and 57 at 24 hours; immune-response genes were predominantly downregulated at the later time point.
Study notes and original source
[Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia].
Medvedeva EV, Dmitrieva VG, Povarova OV, Limborskaia SA, Skvortsova VI, Miasoedov NF, Dergunova LV · Molekuliarnaia biologiia; 2014
PGP altered expression of 29 genes at three hours and 57 at 24 hours; immune-response genes were predominantly downregulated at the later time point.
- Population / setting
- Rat cortical tissue at 3 and 24 hours after permanent focal ischemia
- Source reviewed
- Indexed primary-publication abstract checked; full methods not appraised.
Study limitations
- PGP was tested separately; results cannot be assigned wholesale to Semax or Selank.
- Gene-expression endpoints do not establish clinical stroke efficacy.
Reviewed 2026-10-11.
Review of earlier studies · 2005
Natural and hybrid ("chimeric") stable regulatory glyproline peptides.
The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.
Study notes and original source
Natural and hybrid ("chimeric") stable regulatory glyproline peptides.
Ashmarin IP, Samonina GE, Lyapina LA, Kamenskii AA, Levitskaya NG, Grivennikov IA, Dolotov OV, Andreeva LA, Myasoedov NF · Pathophysiology : the official journal of the International Society for Pathophysiology
The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.
- Population / setting
- Developer synthesis of glyprolin research
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Review of a research program, not an independent trial.
- Specific peptide origin, metabolism and clinical claims require original-source confirmation.
Reviewed 2026-10-05.
Animal research · 2022
Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion.
PGP and PGPL did not reproduce Semax’s gene-expression response after cerebral ischemia in rats. Most measured genes remained unchanged with the shorter peptides, underscoring that a shared PGP motif does not imply equivalent effects.
Study notes and original source
Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion.
Stavchansky VV, Filippenkov IB, Remizova JA, Denisova AE, Mozgovoy IV, Gubsky LV, Myasoedov NF, Andreeva LA, Limborska SA, Dergunova LV · Genes
PGP and PGPL did not reproduce Semax’s gene-expression response after cerebral ischemia in rats. Most measured genes remained unchanged with the shorter peptides, underscoring that a shared PGP motif does not imply equivalent effects.
- Population / setting
- Rat transient middle cerebral artery occlusion; gene-expression assays
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗